Latest Conference Coverage


Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom

Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom

June 22nd 2022

The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]


NeuroVoices: Ruth Benca, MD, PhD, on the Importance of Maintaining Quality Sleep and Lowering Alzheimer Disease Risk

NeuroVoices: Ruth Benca, MD, PhD, on the Importance of Maintaining Quality Sleep and Lowering Alzheimer Disease Risk

June 22nd 2022

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the major talking points regarding sleep quality, sleep disorders, and late-life neurocognitive issues.


Apomorphine Sublingual Film Treatment for Parkinson Disease May Not Require Use of Antiemetics

Apomorphine Sublingual Film Treatment for Parkinson Disease May Not Require Use of Antiemetics

June 20th 2022

After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.


IPX203 Design for Parkinson Disease Might Address Limitations of Current Oral Administrations of Levodopa

IPX203 Design for Parkinson Disease Might Address Limitations of Current Oral Administrations of Levodopa

June 20th 2022

The pharmacodynamic and pharmacokinetic effects of the novel Amneal Pharmaceuticals therapy suggest that it can overcome the current absorption and exposure limitations of the oral levodopa therapies used to treat those with Parkinson disease motor fluctuations.


Highlights of the Advanced Therapeutics in Movement and Related Disorders Congress: Jean Hubble, MD

Highlights of the Advanced Therapeutics in Movement and Related Disorders Congress: Jean Hubble, MD

June 19th 2022

The semi-retired neurologist and consultant with the PMD Alliance offered her takeaways from the 2022 ATMRD Congress in Washington, DC, and her advice for younger clinicians getting into the field. [WATCH TIME: 3 minutes]


The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies

The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies

June 19th 2022

In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.


Perspectives From a Neurology Career in Industry and Academia: Jean Hubble, MD

Perspectives From a Neurology Career in Industry and Academia: Jean Hubble, MD

June 19th 2022

Despite a less than favorable view of the pharmaceutical industry among the general population, there are still benefits to the work being done by clinicians who transition to this line of work according to the semi-retired neurologist and consultant with the PMD Alliance. [WATCH TIME: 2 minutes]


Social Isolation During the COVID-19 Pandemic Negatively Affected Patients With PD, Nonmotor Symptoms

Social Isolation During the COVID-19 Pandemic Negatively Affected Patients With PD, Nonmotor Symptoms

June 19th 2022

Data from a PMD Alliance survey of more than 700 individuals with PD or their care partners showed significant associations between decreased social support and exasperation of nonmotor and cognitive symptoms of PD.


NeurologyLive® Brain Games: June 19, 2022

NeurologyLive® Brain Games: June 19, 2022

June 19th 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.


Physician Estimates of Needle Phobia Might Be Overstated Among Patients With Parkinson Disease

Physician Estimates of Needle Phobia Might Be Overstated Among Patients With Parkinson Disease

June 18th 2022

A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.


The Interdisciplinary Care Team in Movement Disorder Care: Jean Hubble, MD

The Interdisciplinary Care Team in Movement Disorder Care: Jean Hubble, MD

June 18th 2022

The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]


The Importance of Treatment Nuance and Novel Options in Treating Parkinson Disease

The Importance of Treatment Nuance and Novel Options in Treating Parkinson Disease

June 18th 2022

In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.


Number and Severity of Cranial Autonomic Symptoms Differ Based on Cluster Headache, Migraine Aura Status

Number and Severity of Cranial Autonomic Symptoms Differ Based on Cluster Headache, Migraine Aura Status

June 18th 2022

On average, those with cluster headache had 4.8 cranial autonomic symptoms compared with 2.7 for those with migraine, regardless of aura status.


Amantadine Delayed-Release/Extended-Release Capsules Show More Benefit Compared With Other Formulations

Amantadine Delayed-Release/Extended-Release Capsules Show More Benefit Compared With Other Formulations

June 18th 2022

In a first, but indirect, comparison of the 3 available formulations of amantadine for the treatment of Parkinson disease, only the delayed-release/extended-release formulation (Gocovri) resulted in improvements in both in OFF time and dyskinesia.


Social Prescribing and Advances in Therapy for Movement Disorders: Jean Hubble, MD

Social Prescribing and Advances in Therapy for Movement Disorders: Jean Hubble, MD

June 17th 2022

The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]


Opicapone Shows Comparable Efficacy, Safety Among Older Individuals With Parkinson Disease

Opicapone Shows Comparable Efficacy, Safety Among Older Individuals With Parkinson Disease

June 17th 2022

The investigators noted that the data on tolerability and efficacy support that treatment with opicapone among older adults with PD requires no age-related dose adjustments.


Next Steps in Understanding Patterns of Difficulty Initiating Sleep Among Races, Genders: Afsara Zaheed

Next Steps in Understanding Patterns of Difficulty Initiating Sleep Among Races, Genders: Afsara Zaheed

June 17th 2022

The graduate student at the University of Michigan provided insight on the ways to expand the current knowledge about the disparities among races and genders in sleep quality and long-term cognitive outcomes. [WATCH TIME: 3 minutes]


MAGNIMS Score Successfully Predicts Risk of Long-Term of Disability Accumulation

MAGNIMS Score Successfully Predicts Risk of Long-Term of Disability Accumulation

June 17th 2022

In the comparator study between ponesimod and teriflunomide, the risk of both 12- and 24-week confirmed disability accumulation at week 108 was significantly different between MAGNIMS score groups.


Episode 66: 2022 SLEEP Annual Meeting Highlights

Episode 66: 2022 SLEEP Annual Meeting Highlights

June 17th 2022

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Afsara Zaheed; Richard Bogan, MD, FCCP, FAASM; and Ruth Benca, MD, PhD. [LISTEN TIME: 18 minutes]


Understanding Treatment Decisions and Differences Between Diroximel Fumarate and Dimethyl Fumarate

Understanding Treatment Decisions and Differences Between Diroximel Fumarate and Dimethyl Fumarate

June 16th 2022

Meghan Garabedian, CRNP, MSN, nurse practitioner at the Penn Neuroscience Center, discussed her presentation at the 2022 CMSC Annual Meeting regarding the patient experience on diroximel fumarate.


Improving the Understanding of Narcolepsy and its Pathophysiology: Richard Bogan, MD, FCCP, FAASM

Improving the Understanding of Narcolepsy and its Pathophysiology: Richard Bogan, MD, FCCP, FAASM

June 16th 2022

The associate clinical professor at the University of South Carolina School of Medicine discussed the strides, but also challenges still in treating patients with narcolepsy. [WATCH TIME: 2 minutes]


Patient-Reported Outcomes Favor Erenumab Over Topiramate for Migraine in HER-MES Study

Patient-Reported Outcomes Favor Erenumab Over Topiramate for Migraine in HER-MES Study

June 16th 2022

Over a 24-week treatment period, 72.2% of those on erenumab achieved relevant improvement on HIT-6 scores compared with 53.9% of those on topiramate.


Feasibility of Incorporating an Interprofessional Student Program to Other Institutions, Universities: Stephanie Teixeira-Poit, PhD

Feasibility of Incorporating an Interprofessional Student Program to Other Institutions, Universities: Stephanie Teixeira-Poit, PhD

June 16th 2022

The associate professor at the North Carolina Agricultural and Technical State University provided insight on the widespread feasibility of a new initiative that aims to teach and attract young professionals to the MS field. [WATCH TIME: 4 minutes]


Dose-Dependent Weight Reductions Observed With Atogepant

Dose-Dependent Weight Reductions Observed With Atogepant

June 15th 2022

In the open-label extension where the highest dose of atogepant (Qulipta; AbbVie) was observed, 24.1% of participants had at least 7% weight loss compared with 14.7% of those on standard of care.


The Effect of Mindfulness Practices on Migraine: Paige Estave, PhD

The Effect of Mindfulness Practices on Migraine: Paige Estave, PhD

June 15th 2022

The MD-PhD student at Wake Forest School of Medicine shared her perspective on the findings of a study suggesting that mindfulness practices can alter pain perception and migraine attack awareness, among other results. [WATCH TIME: 4 minutes]


NeuroVoices: Tanuja Chitnis, MD, on Targeting Anti-CD3, Other Biomarkers in Progressive Multiple Sclerosis

NeuroVoices: Tanuja Chitnis, MD, on Targeting Anti-CD3, Other Biomarkers in Progressive Multiple Sclerosis

June 15th 2022

The associate neurologist at Brigham and Women’s Hospital discussed the potential of a nasal anti-CD3 monoclonal antibody, foralumab, and its impact on biomarkers specific to patients with progressive multiple sclerosis.


2022 SMA Research & Clinical Care Meeting: What to Expect

2022 SMA Research & Clinical Care Meeting: What to Expect

June 14th 2022

Mary Schroth, MD, and Jacqueline Glascock, PhD, of Cure SMA, share their perspectives on the upcoming annual meeting.


Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms

Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms

June 14th 2022

A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.

© 2025 MJH Life Sciences

All rights reserved.